Table 2.

Overall survival curve adjustment: HR and adjustment factor for all patients (stage IIIB–IV M1c)

Trial (drug, patient population)	HR for comparators	HR for GM-CSF	Adjustment factor
CA184-024 (dacarbazine, previously untreated) [8]	0.32	0.22	0.69
BRIM-3 (dacarbazine, previously untreated) [10]	0.32	0.22	0.69
BREAK-3 (dacarbazine, previously untreated) [9]	0.29	0.22	0.76
Daponte (dacarbazine, previously untreated) [25]	0.39	0.22	0.57
MDX010-20 (gp100, previously treated) [7]	0.34	0.22	0.65

GM-CSF granulocyte-macrophage colony-stimulating factor, gp100 glycoprotein 100, HR hazard ratio